Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age

NCT00971906 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

660

Enrollment

INDUSTRY

Sponsor class

Conditions

Pandemic Influenza

Interventions

BIOLOGICAL: Monovalent A/H1N1 influenza vaccine

Sponsor

Novartis Vaccines